| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Advances in Brief |
Department of Otolaryngology, Division of Head and Neck Cancer Research [M. S-C., L. W., J. J., D. S.], and Departments of Oncology Biostatistics [S. P.], Pathology [W. H. W.], and Surgery [S. C. Y], Johns Hopkins University School of Medicine, Baltimore, Maryland 21206-2198; Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin 53226 [S. A. A.]; and Medical Oncology Department, Hospital Universitari Germans Trias I Pujol, Badalona, 08916 Barcelona, Spain [R. R., M .M.]
The etiology of lung tumors arising in nonsmokers remains unclear.
Although mutations in the K-ras and p53
genes have been reported to be significantly higher in
smoking-related lung carcinomas, in the present study we performed a
more comprehensive analysis in search of additional genetic changes
between lung adenocarcinoma from tobacco- and non-tobacco-exposed
patients. We selected a matched cohort of 18 lifetime nonsmoking and 27
smoking patients diagnosed with primary adenocarcinoma of the lung and
searched for chromosomal alterations in each tumor by testing normal
and tumor tissue with 54 highly polymorphic microsatellite markers
located on 28 different chromosomal arms. Allelic losses or gains at
chromosomal arms 3p (37 versus 6%), 6q (46
versus 12%), 9p (65 versus 22%), 16p
(28 versus 0%), 17p (45
versus 11%), and 19p (58 versus 16%)
were present significantly more often in adenocarcinomas from smokers
than from nonsmokers. Chromosomal arms showing allelic imbalance in
lung tumors from nonsmokers were rare but occurred more often at 19q
(22%), 12p (22%), and 9p (22%). The FAL (fractional allelic loss or
gain) is defined as the percentage of chromosomal arm losses/gains
among the total informative chromosomal arms. Tumors from smokers
harbored higher levels of FAL (13 (48%) of 27 showed FAL 
0.3) compared with the lung tumors from the nonsmoker patients
(2 (11%) of 18 showed FAL 0.3;
P = 0.02; odds ratio,
0.13; 95% confidence interval, 0.01–0.79). Our data
demonstrate that widespread chromosomal abnormalities are frequent in
lung adenocarcinoma from smokers, whereas these abnormalities are
infrequent in such tumors arising in nonsmokers. These observations
support the notion that lung cancers in nonsmokers arise through
genetic alterations distinct from the common events observed in tumors
from smokers.
This article has been cited by other articles:
|
|
 |
|
  B. Weissman and K. E. Knudsen Hijacking the Chromatin Remodeling Machinery: Impact of SWI/SNF Perturbations in Cancer Cancer Res., November 1, 2009; 69(21): 8223 - 8230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Rodriguez-Nieto and M. Sanchez-Cespedes BRG1 and LKB1: tales of two tumor suppressor genes on chromosome 19p and lung cancer Carcinogenesis, April 1, 2009; 30(4): 547 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. Massion, Y. Zou, H. Chen, A. Jiang, P. Coulson, C. I. Amos, X. Wu, I. Wistuba, Q. Wei, Y. Shyr, et al. Smoking-related Genomic Signatures in Non-Small Cell Lung Cancer Am. J. Respir. Crit. Care Med., December 1, 2008; 178(11): 1164 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Ruosaari, P. E.H. Nymark, M. M. Aavikko, E. Kettunen, S. Knuutila, J. Hollmen, H. Norppa, and S. L. Anttila Aberrations of chromosome 19 in asbestos-associated lung cancer and in asbestos-induced micronuclei of bronchial epithelial cells in vitro Carcinogenesis, May 1, 2008; 29(5): 913 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Feng, S. E. Hawes, J. E. Stern, L. Wiens, H. Lu, Z. M. Dong, C. D. Jordan, N. B. Kiviat, and H. Vesselle DNA Methylation in Tumor and Matched Normal Tissues from Non-Small Cell Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 645 - 654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. D. Bonomi, L. Buckingham, and J. Coon Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors Clin. Cancer Res., August 1, 2007; 13(15): 4606s - 4612s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cappuzzo, C. Ligorio, P. A. Janne, L. Toschi, E. Rossi, R. Trisolini, D. Paioli, A. J. Holmes, E. Magrini, G. Finocchiaro, et al. Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization-Positive/Phospho-Akt-Positive or Never Smoker Patients With Advanced Non-Small-Cell Lung Cancer: The ONCOBELL Trial J. Clin. Oncol., June 1, 2007; 25(16): 2248 - 2255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Subramanian and R. Govindan Lung Cancer in Never Smokers: A Review J. Clin. Oncol., February 10, 2007; 25(5): 561 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Karamouzis, P. A. Konstantinopoulos, and A. G. Papavassiliou The Activator Protein-1 Transcription Factor in Respiratory Epithelium Carcinogenesis Mol. Cancer Res., February 1, 2007; 5(2): 109 - 120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Ueda, M. Jinbo, T.-S. Li, T. Yagi, K. Suga, and K. Hamano Computed Tomography-Diagnosed Emphysema, Not Airway Obstruction, Is Associated with the Prognostic Outcome of Early-Stage Lung Cancer. Clin. Cancer Res., November 15, 2006; 12(22): 6730 - 6736. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Dutu, S. Michiels, P. Fouret, F. Penault-Llorca, P. Validire, S. Benhamou, E. Taranchon, L. Morat, D. Grunenwald, T. Le Chevalier, et al. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers Ann. Onc., December 1, 2005; 16(12): 1906 - 1914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Eberhard, B. E. Johnson, L. C. Amler, A. D. Goddard, S. L. Heldens, R. S. Herbst, W. L. Ince, P. A. Janne, T. Januario, D. H. Johnson, et al. Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non-Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib J. Clin. Oncol., September 1, 2005; 23(25): 5900 - 5909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B. E. Johnson, A. Sandler, M. G. Kris, H. T. Tran, P. Klein, X. Li, et al. TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 2005; 23(25): 5892 - 5899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Zheng, G. Bepler, A. Cantor, and E. B. Haura Small Tumor Size and Limited Smoking History Predicts Activated Epidermal Growth Factor Receptor in Early-Stage Non-small Cell Lung Cancer Chest, July 1, 2005; 128(1): 308 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Pao and V. A. Miller Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non-Small-Cell Lung Cancer: Current Knowledge and Future Directions J. Clin. Oncol., April 10, 2005; 23(11): 2556 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Pan, J. Califano, J. F. Ponte, A. L. Russo, K.-h. Cheng, A. Thiagalingam, P. Nemani, D. Sidransky, and S. Thiagalingam Loss of Heterozygosity Patterns Provide Fingerprints for Genetic Heterogeneity in Multistep Cancer Progression of Tobacco Smoke-Induced Non-Small Cell Lung Cancer Cancer Res., March 1, 2005; 65(5): 1664 - 1669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Singh, A. P. Sowjanya, and G. Ramakrishna The wild-type Ras: road ahead FASEB J, February 1, 2005; 19(2): 161 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.C. AMLER, A.D. GODDARD, and K.J. HILLAN Predicting Clinical Benefit in Non-Small-Cell Lung Cancer Patients Treated with Epidermal Growth Factor Tyrosine Kinase Inhibitors Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 483 - 488. [Abstract] [PDF]
|
|
|
|
|
|
P. J. Mazzone, T. Mekhail, and A. C. Arroliga Is Lung Cancer in the Nonsmoker a Different Disease? Chest, August 1, 2004; 126(2): 326 - 329. [Full Text] [PDF]
|
|
|
|
|
|
L. T. Nordquist, G. R. Simon, A. Cantor, W. M. Alberts, and G. Bepler Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung Chest, August 1, 2004; 126(2): 347 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Miller, M. G. Kris, N. Shah, J. Patel, C. Azzoli, J. Gomez, L. M. Krug, W. Pao, N. Rizvi, B. Pizzo, et al. Bronchioloalveolar Pathologic Subtype and Smoking History Predict Sensitivity to Gefitinib in Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., March 15, 2004; 22(6): 1103 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Tammemagi, C. Neslund-Dudas, M. Simoff, and P. Kvale Smoking and Lung Cancer Survival: The Role of Comorbidity and Treatment Chest, January 1, 2004; 125(1): 27 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Knowles, T. Habuchi, W. Kennedy, and D. Cuthbert-Heavens Mutation Spectrum of the 9q34 Tuberous Sclerosis Gene TSC1 in Transitional Cell Carcinoma of the Bladder Cancer Res., November 15, 2003; 63(22): 7652 - 7656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Medina, S. A. Ahrendt, M. Pollan, P. Fernandez, D. Sidransky, and M. Sanchez-Cespedes Screening of Homologous Recombination Gene Polymorphisms in Lung Cancer Patients Reveals an Association of the NBS1-185Gln Variant and p53 Gene Mutations Cancer Epidemiol. Biomarkers Prev., August 1, 2003; 12(8): 699 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. I. Jimenez, P. Fernandez, O. Dominguez, A. Dopazo, and M. Sanchez-Cespedes Growth and Molecular Profile of Lung Cancer Cells Expressing Ectopic LKB1: Down-Regulation of the Phosphatidylinositol 3'-Phosphate Kinase/PTEN Pathway Cancer Res., March 15, 2003; 63(6): 1382 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cave-Riant, B. Cuillerier, M. Beau-Faller, N. Martinet, F. Alla, C. Bronner, A. Schneider, P. Oudet, and M. P. Gaub Association of Genetic Defects in Primary Resected Lung Adenocarcinoma Revealed by Targeted Allelic Imbalance Analysis Am. J. Respir. Cell Mol. Biol., October 1, 2002; 27(4): 495 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ozaki, K.-L. Schaefer, D. Wai, R. Yokoyama, S. Ahrens, R. Diallo, T. Hasegawa, T. Shimoda, S. Hirohashi, A. Kawai, et al. Population-based genetic alterations in Ewing's tumors from Japanese and European Caucasian patients Ann. Onc., October 1, 2002; 13(10): 1656 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Wong, W. K. Lam, E. Wang, S. W. Chiu, C. L. Lam, and L. P. Chung Primary Adenocarcinomas of the Lung in Nonsmokers Show a Distinct Pattern of Allelic Imbalance Cancer Res., August 1, 2002; 62(15): 4464 - 4468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J. M. Engles, W. H. Westra, J. G. Herman, and D. Sidransky Inactivation of LKB1/STK11 Is a Common Event in Adenocarcinomas of the Lung Cancer Res., July 1, 2002; 62(13): 3659 - 3662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fujii, T. Dracheva, A. Player, S. Chacko, R. Clifford, R. L. Strausberg, K. Buetow, N. Azumi, W. D. Travis, and J. Jen A Preliminary Transcriptome Map of Non-Small Cell Lung Cancer Cancer Res., June 1, 2002; 62(12): 3340 - 3346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mora, N.-K. V. Cheung, S. Oplanich, L. Chen, and W. L. Gerald Novel Regions of Allelic Imbalance Identified by Genome-wide Analysis of Neuroblastoma Cancer Res., March 1, 2002; 62(6): 1761 - 1767. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
